Why Cooper Earnings Could Look Healthier

Why Cooper Earnings Could Look Healthier

Cooper will release its quarterly report on Thursday, and with the stock trading at all-time highs, investors are looking for strong results from the company. Despite some headwinds that have hurt other medical-device makers, Cooper earnings appear likely to grow both this quarter and well into the future.

Cooper has focused on two major segments for its success. On one hand, it makes vision-care products, with an emphasis on contact lenses. Yet Cooper also makes products to supply medical professionals specializing in obstetrics and gynecology, with the goal of improving health care delivery to women. Let's take an early look at what's been happening with Cooper over the past quarter and what we're likely to see in its report.

Stats on Cooper

Analyst EPS Estimate


Change From Year-Ago EPS


Revenue Estimate

$410.54 million

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

How far can Cooper earnings climb?
Analysts have gotten more optimistic about the prospects for Cooper earnings in recent months, boosting their July quarter estimates by a nickel per share and their full fiscal-year projections by more than triple that amount. The stock has continued its strong move upward, rising 17% since late May.

Cooper carried its positive momentum from last quarter, reporting solid results from its fiscal second quarter. Earnings climbed 36% on an 11% jump in revenue, with CEO Bob Weiss specifically referring to the company's newly launched MyDay single-use contact lenses as an example of its success in delivering on its long-term goals. The company managed to increase its margins in part by cutting royalty payments on its silicone hydrogel lens sales, and Cooper also reduced its outstanding debt by more than a fifth during the quarter.

Part of Cooper's success has come from identifying and delivering on customers' wants and needs. In vision, sales of one-day contact lenses carry much higher profit margins than its monthly lenses. That's consistent with the experience of health care giant Johnson & Johnson , which also specifically noted daily lenses as a growth opportunity for its worldwide vision-care business. Cooper recently got an analyst upgrade that cited continued strength in contact lens sales in projecting a favorable outcome for shareholders.

But Cooper has also been smart about strategic moves. In May, it announced the sale of its Asahikasei Aime unit to Nippon Contact Lens. The original purchase of the unit in 2010 helped Cooper with sales of its Biofinity contact lenses in Japan, but the unit's weaker margins led Cooper to seek to sell it off.

One key question for Cooper is whether it could be a takeover target. Valeant Pharmaceuticals' $8.7 billion purchase of Bausch & Lomb heightened awareness of the value of vision-related businesses. With Cooper's market cap at $6.4 billion, a takeover deal would likely cost about the same amount including an acquisition premium.

In the Cooper earnings report, watch to see how the company's market share in the contact-lens market is faring, especially with its new one-day offerings. In addition, with the women's-health unit having posted faster revenue growth in past quarters, you'll want to pay attention to whether that trend continues to support Cooper's overall growth rates.

One of the biggest questions facing health-care companies of all kinds is how Obamacare will affect their fortunes. In this free report, our analysts walk you through the opportunities that Obamacare presents for the health-care industry and the companies that are positioned to exploit them. The informational edge contained in it is invaluable, but can only be exploited profitably while the rest of the market remains in the dark. To access this free report instantly, simply click here now.

Click here to add Cooper to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

The article Why Cooper Earnings Could Look Healthier originally appeared on Fool.com.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.